High cofilin-1 levels correlate with cisplatin resistance in lung adenocarcinomas

Tumor Biology

Volumn 35, Issue 2, 2014, Pages 1233-1238

  Becker, Matheus ^a,b   De Bastiani, Marco Antônio ^a,b   Müller, Carolina Beatriz ^a,b   Markoski, Melissa M ^c   Castro, Mauro Antônio A ^b,d   Klamt, Fábio ^a,b  

^a Instituto de Ciencias Biologicas e da Saude Pontifical Catholic University of Minas Gerais   (Brazil)

^b Instituto Nacional de Ciência e Tecnologia Translacional em Medicina INCT TM   (Brazil)

^c INSTITUTO DE CARDIOLOGIA DO RIO GRANDE DO SUL   (Brazil)

^d HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

CFL1; Cisplatin resistance; Cofilin 1; Non small cell lung cancer; Predictive biomarker

Indexed keywords

CISPLATIN; COFILIN 1; TUMOR MARKER;

ARTICLE; BOOTSTRAPPING; CANCER CELL; CANCER CHEMOTHERAPY; CORRELATION ANALYSIS; DRUG CYTOTOXICITY; GENE EXPRESSION; GENE INTERACTION; GENE REGULATORY NETWORK; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; TRANSIENT TRANSFECTION;

ADENOCARCINOMA; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CISPLATIN; COFILIN 1; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; PROGNOSIS;

EID: 84899050727     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1164-6     Document Type: Article

References (31)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
2. Detterbeck FC, Mazzone PJ, Naidich DP, Bach PB. Screening for lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e78S-92S.
3. Heist RS, Engelman JA. SnapShot: non-small cell lung cancer. Cancer Cell. 2012;21:448-8. e2.
4. Cho WC. Potentially useful biomarkers for the diagnosis, treatment and prognosis of lung cancer. Biomed Pharmacother. 2007;61:515-9.
5. Chen X, Liu Y, Røe OD, Qian Y, Guo R, Zhu L, et al. Gefitinib or erlotinib asmaintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review. PLoS One. 2013;8(3):e59314.
6. Nana-Sinkam SP, Powell CA. Molecular biology of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e30S-9S.
7. Müller CB, de Barros RL, Moreira JCF, Klamt F. Bioinformatics approach for the validation of non-small cell lung cancer biomarkers. Front Biosci. 2011;3:46-50.
8. Castro MA, Dal-Pizzol F, Zdanov S, Soares M, Müller CB, Lopes FM, et al. CFL1 expression levels as a prognostic and drug resistance marker in nonsmall cell lung cancer. Cancer. 2010;116:3645-55.
9. Müller CB, de Barros RL, Castro MAA, Lopes FM, Meurer RT, Roehe A, et al. Validation of cofilin-1 as a biomarker in non-small cell lung cancer: application of quantitative method in a retrospective cohort. J Cancer Res Clin Oncol. 2011;137:1309-16.
10. Wang W, Eddy R, Condeelis J. The cofilin pathway in breast cancer invasion and metastasis. Nat Rev Cancer. 2009;7:429-40. (Pubitemid 46809168)
11. Klamt F, Zdanov S, Levine RL, Pariser A, Zhang Y, Zhang B, et al. Oxidant-induced apoptosis is mediated by oxidation of the actin-regulatory protein cofilin. Nat Cell Biol. 2009;11:1241-6.
12. Sinha P, Hütter G, Köttgen E, Dietel M, Schadendorf D, Lage H. Increased expression of epidermal fatty acid binding protein, cofilin, and 14-3-3-sigma (stratifin) detected by two-dimensional gel electrophoresis, mass spectrometry and microsequencing of drug-resistant human adenocarcinoma of the pancreas. Electrophoresis. 1999;20(14):2952-60. (Pubitemid 29517227)
13. Gunnersen JM, Spirkoska V, Smith PE, Danks RA, Tan SS. Growth and migration markers of rat C6 glioma cells identified by serial analysis of gene expression. Glia. 2000;32(2):146-54.
14. Keshamouni VG, Michailidis G, Grasso CS, Anthwal S, Strahler JR, Walker A, et al. Differential protein expression profiling by iTRAQ-2DLC-MS/MS of lung cancer cells undergoing epithelial-mesenchymal transition reveals a migratory/invasive phenotype. J Proteome Res. 2006;5(5):1143-54. (Pubitemid 43727792)
15. Wang W, Mouneimne G, Sidani M, Wyckoff J, Chen X, Makris A, et al. The activity status of cofilin is directly related to invasion, intravasation, and metastasis of mammary tumors. J Cell Biol. 2006;173(3):395-404.
16. Gemma A, Li C, Sugiyama Y, Matsuda K, Seike Y, Kosaihira S, et al. Anticancer drug clustering in lung cancer based on gene expression profiles and sensitivity database. BMC Cancer. 2006;6:174.
17. Castro MA, Filho JL, Dalmolin RJ, Sinigaglia M, Moreira JC, Mombach JC, et al. ViaComplex: software for landscape analysis of gene expression networks in genomic context. Bioinformatics. 2009;25(11):1468-9.
18. Giroux Leprieur E, Antoine M, Vieira T, Duruisseaux M, Poulot V, Rabbe N, et al. Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy. Lung Cancer. 2013;79(2):167- 72.
19. Crawford S. Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy. Front Pharmacol. 2013;4:68.
20. Wang LH, Xiang J, Yan M, Zhang Y, Zhao Y, Yue CF, et al. The mitotic kinase Aurora-A induces mammary cell migration and breast cancer metastasis by activating the cofilin-F-actin pathway. Cancer Res. 2010;70(22):9118-28.
21. Polachini GM, Sobral LM, Mercante AM, Paes-Leme AF, Xavier FCA, Henrique T, et al. Proteomic approaches identify members of cofilin pathway involved in oral tumorigenesis. PLoS One. 2012;7(12):e50517.
22. Yang ZL, Miao X, Xiong L, Zou Q, Yuan Y, Li J, et al. CFL1 and Arp3 are biomarkers for metastasis and poor prognosis of squamous cell/adenosquamous carcinomas and adenocarcinomas of gallbladder. Cancer Invest. 2013;31(2):132-9.
23. van Rheenen J, Song X, van Roosmalen W, Cammer M, Chen X, Desmarais V, et al. EGF-induced PIP2 hydrolysis releases and activates cofilin locally in carcinoma cells. J Cell Biol. 2007;179(6):1247-59. (Pubitemid 350277742)
24. Oser M, Condeelis J. The cofilin activity cycle in lamellipodia and invadopodia. J Cell Biochem. 2009;108(6):1252-62.
25. Kotiadis VN, Leadsham JE, Bastow EL, Gheeraert A, Whybrew JM, Bard M, et al. Identification of new surfaces of cofilin that link mitochondrial function to the control of multi-drug resistance. J Cell Sci. 2012;125:2288-99.
26. Yan XD, Pan LY, Yuan Y, Lang JH, Mao N. Identification of platinum-resistance associated proteins through proteomic analysis of human ovarian cancer cells and their platinum-resistant sublines. J Proteome Res. 2007;6(2):772-80. (Pubitemid 46340180)
27. Wei R, Zhang Y, Shen L, Jiang W, Li C, Zhong M, et al. Comparative proteomic and radiobiological analyses in human lung adenocarcinoma cells. Mol Cell Biochem. 2012;359(1-2):151-9.
28. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869-83.
29. Ihnatovych I, Livak M, Reed J, de Lanerolle P, Strakova Z. Manipulating actin dynamics affects human in vitro decidualization. Biol Reprod. 2009;81(1):222-30.
30. Samstag Y, Eckerskorn C, Wesselborg S, Henning S, Wallich R, Meuer SC. Costimulatory signals for human T-cell activation induce nuclear translocation of pp 19/cofilin. Proc Natl Acad Sci U S A. 1994;91(10):4494-8. (Pubitemid 24143460)
31. Nebl G, Meuer SC, Samstag Y. Dephosphorylation of serine 3 regulates nuclear translocation of cofilin. J Biol Chem. 1996;271(42):26276-80. (Pubitemid 26347477)